CAJ | 학술논문

目的：探讨前列腺特异性抗原前体（p2PSA）相关指标价值及其与年龄相关性。方法对238名10～90岁年龄段马鞍山地区健康男性统一检测PSA和p2PSA等指标，按每10岁一组分8组，分别统计分析各组p2PSA和%p2PSA均值及其95%可信区间，与tPSA、fPSA及%fPSA等指标综合对比，绘制年龄相关曲线并分析曲线特征。结果 p2PSA 与 tPSA 曲线均随年龄增加而总体呈上升趋势。tPSA曲线以40岁为标志性临界点（1.0 ng/ml），p2PSA曲线按年龄段可划分为3个阶段：即p2PSA上升低区（0～29岁，95%CI 2.22～5.91 pg/ml）、波动上升期（30～59岁，95%CI 4.66～11.74 pg/ml）和老年上升期（60～89岁，95% CI 7.44～18.63 pg/ml）。其中40～49岁区间， p2PSA由5.24 pg/ml快速升至9.93 pg/ml，年增速度0.47 pg/ml，显著大于tPSA增速（P＜0.001）。70岁后，与tPSA转为下降趋势完全不同，p2PSA依然继续上升。40岁之前，%p2PSA曲线与%fPSA相似，呈总体下降趋势。但40～49岁期间走势与%fPSA下降趋势完全相反，由17.01再次快速上升，在45岁左右与%fPSA曲线交叉，至50～59岁期间达到26.65，为终生最高峰。p2PSA/tPSA曲线与年龄相关性较小，10岁后曲线终生都相对平稳，波动于5～10之间。结论 p2PSA及%p2PSA指标与PSA一样，也呈现年龄相关性特点。同时结合多指标和患者年龄因素综合分析判断在临床各方面潜在价值可能优于以往单一PSA指标。
목적：탐토전렬선특이성항원전체（p2PSA）상관지표개치급기여년령상관성。방법대238명10～90세년령단마안산지구건강남성통일검측PSA화p2PSA등지표，안매10세일조분8조，분별통계분석각조p2PSA화%p2PSA균치급기95%가신구간，여tPSA、fPSA급%fPSA등지표종합대비，회제년령상관곡선병분석곡선특정。결과 p2PSA 여 tPSA 곡선균수년령증가이총체정상승추세。tPSA곡선이40세위표지성림계점（1.0 ng/ml），p2PSA곡선안년령단가화분위3개계단：즉p2PSA상승저구（0～29세，95%CI 2.22～5.91 pg/ml）、파동상승기（30～59세，95%CI 4.66～11.74 pg/ml）화노년상승기（60～89세，95% CI 7.44～18.63 pg/ml）。기중40～49세구간， p2PSA유5.24 pg/ml쾌속승지9.93 pg/ml，년증속도0.47 pg/ml，현저대우tPSA증속（P＜0.001）。70세후，여tPSA전위하강추세완전불동，p2PSA의연계속상승。40세지전，%p2PSA곡선여%fPSA상사，정총체하강추세。단40～49세기간주세여%fPSA하강추세완전상반，유17.01재차쾌속상승，재45세좌우여%fPSA곡선교차，지50～59세기간체도26.65，위종생최고봉。p2PSA/tPSA곡선여년령상관성교소，10세후곡선종생도상대평은，파동우5～10지간。결론 p2PSA급%p2PSA지표여PSA일양，야정현년령상관성특점。동시결합다지표화환자년령인소종합분석판단재림상각방면잠재개치가능우우이왕단일PSA지표。
Objective To study the relationships among p2PSA, %p2PSA and male ages, and to contrast some potential values of p2PSA and%p2PSA with conventional PSA tumor markers. Methods 238 healthy men, aged from 10-90, were simultaneously detected tPSA, fPSA and p2PSA levels in their sera. The mean levels and 95%confidence intervals were classified with every 10 years old into 8 groups, and these data were analyzed by SPSS 19.0 statistics software. The features among tPSA, fPSA, %fPSA, p2PSA and %p2PSA were mainly studied on their age-related distribution curves. Results With age increasing, the levels of tPSA and p2PSA were both overall climbed. As the critical point of age 40 when tPSA was just exactly climbing at 1.0 ng/ml, p2PSA curve could be segmentalized into 3 stages: initial climbout (aged 0-29, 95%CI 2.22-5.91), fluctuating upgrade (aged 30-59, 95%CI 4.66-11.74) and senile increasing (aged 60-89, 95%CI 7.44-18.63). Moreover, between aged 40-49, p2PSA zoomly rise from 5.24 to 9.93 with a rapid speed of 0.47pg/ml per year, which was even fast than tPSA (P<0.001). What's more, p2PSA level yet showed continually climbing after 70 years old, whereas tPSA had already stepped downhill. With regard to%p2PSA, before aged 40,%p2PSA curve was somewhat similar to%fPSA which were both in gradually decreasing trends. However, in the range of aged 40-49, by contrast to%fPSA curve still declining, %p2PSA curve showed second rapid climbing from 17.01. After up-crossed with %fPSA curve at about 45 years old,%p2PSA curve attained to 26.65 as a lifetime peak in aged 50-59. Nevertheless, the p2PSA/tPSA curve had less influence by age which had a lifetime fluctuations in the range of 5-10. Conclusions p2PSA and %p2PSA also have intimate relationships with age other than some different characteristic compared with tPSA, fPSA and %fPSA. Moreover, simultaneously pondering p2PSA and %p2PSA levels and age for comprehensive analyses and judgements might probably harvest more values in clinical diagnoses and treatments than conventional tumor marker of single PSA.